Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosentan for sudden visual loss in giant cell arteritis
2018-004072-35Phase 3Completed
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Nov 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of bosentan in giant cell arteritis (GCA), sponsored by Centre Hospitalier Universitaire de Nice. Primary endpoint: Visual acuity at 3 months. Started Nov 2018; status: completed.
02
Drugs
bosentan
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on 2018-004072-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004072-35.